{"nctId":"NCT01816165","briefTitle":"Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes","startDateStruct":{"date":"2011-06"},"conditions":["Type 1 Diabetes"],"count":28,"armGroups":[{"label":"Acipimox","type":"EXPERIMENTAL","interventionNames":["Drug: Acipimox"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Acipimox","otherNames":["Olbetam"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Men and women, with and without type 1 diabetes between 25-59 years of age,\n2. HbA1c 6.0-9.5 (T1D only),\n3. Subjects who are willing to commit to:\n\n   * 14 days of prescribed diet,\n   * two 44 hour inpatient stays, and\n   * two muscle biopsies.\n\nExclusion Criteria:\n\n1. Any comorbid condition associated with inflammation, insulin resistance, or dyslipidemia,\n2. Tobacco use,\n3. Pregnancy,\n4. Steroid use,\n5. Scheduled physical activity \\>3 days a week,\n6. Angina or any other cardiovascular or pulmonary disease,\n7. History of chronic obstructive pulmonary disease or asthma,\n8. Systolic blood pressure \\>190 at rest or \\>250 with exercise, or\n9. Diastolic pressure \\>95 at rest, or \\>105 with exercise,\n10. Proteinuria (urine protein \\>200 mg/dl), or\n11. Creatinine \\> 2 mg/dl, suggestive of severe renal disease,\n12. Severe Proliferative retinopathy,\n13. Niacin treatment,\n14. History of peptic ulcers,\n15. History of hereditary angioedema, and\n16. C1 esterase deficiency.","healthyVolunteers":true,"sex":"ALL","minimumAge":"25 Years","maximumAge":"59 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Insulin Sensitivity: M-value From Hyperinsulinemic Euglycemia Clamp Study","description":"Evaluate the impact of Non esterified fatty acid (NEFA)-lowering on insulin sensitivity in T1D versus non-DM. Glucose infusion rate is reported normalized to lean body weight in kg and to final insulin concentration.\n\nThe unit of measure reflects the rate at which glucose needs to be infused to maintain a normal blood sugar in the setting of a given serum insulin level from an insulin infusion. As such, a higher number means more glucose was needed and indicates greater sensitivity to insulin.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.65","spread":"1.52"},{"groupId":"OG001","value":"3.67","spread":"1.45"},{"groupId":"OG002","value":"8.8","spread":"3.04"},{"groupId":"OG003","value":"9.05","spread":"2.88"}]}]}]},{"type":"PRIMARY","title":"24 Hour Mean Fatty Acid Levels","description":"Assesses whether fatty acid level is consistently lowered by acipimox. Mean of fatty acid levels measured 22 times over 24 hours (hourly except 0100 and 0300 hours).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"343","spread":"122"},{"groupId":"OG001","value":"297","spread":"56"},{"groupId":"OG002","value":"298","spread":"90"},{"groupId":"OG003","value":"335","spread":"65"}]}]}]},{"type":"PRIMARY","title":"Percent Flow-mediated Brachial Artery Dilation","description":"To determine the effects of NEFA lowering and insulin sensitization on endothelial function. Measures percent change in brachial artery diameter with hyperemia after occlusion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.21","spread":"3.02"},{"groupId":"OG001","value":"8.82","spread":"4.40"},{"groupId":"OG002","value":"5.88","spread":"4.17"},{"groupId":"OG003","value":"7.32","spread":"4.25"}]}]}]},{"type":"PRIMARY","title":"State 3 Mitochondrial Oxygen Consumption","description":"Measures skeletal muscle mitochondrial function and effects of acipimox thereon, carbohydrate \\& lipid substrates. State 3 is fully active coupled oxygen flux using PMG or PMGS (pyruvate, malate, glutamate, +/- succinate) or OCMS (octanyl carnitine, malate, +/- succinate) as substrates. FCCP is added as an uncoupler to measure maximum possible O2 flux. Higher values reflect better mitochondrial function.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.1","spread":"8.3"},{"groupId":"OG001","value":"24.9","spread":"7.6"},{"groupId":"OG002","value":"30.2","spread":"9.8"},{"groupId":"OG003","value":"29.7","spread":"10.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.0","spread":"11.8"},{"groupId":"OG001","value":"36.9","spread":"12.7"},{"groupId":"OG002","value":"42.5","spread":"15.0"},{"groupId":"OG003","value":"42.5","spread":"11.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.2","spread":"18.4"},{"groupId":"OG001","value":"62.1","spread":"16.3"},{"groupId":"OG002","value":"77.8","spread":"26.3"},{"groupId":"OG003","value":"80.2","spread":"28.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":"5.8"},{"groupId":"OG001","value":"15.0","spread":"5.6"},{"groupId":"OG002","value":"18.8","spread":"8.6"},{"groupId":"OG003","value":"17.3","spread":"4.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.6","spread":"14.6"},{"groupId":"OG001","value":"38.5","spread":"11.2"},{"groupId":"OG002","value":"43.8","spread":"13.3"},{"groupId":"OG003","value":"41.7","spread":"9.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.8","spread":"22.9"},{"groupId":"OG001","value":"56.4","spread":"20.0"},{"groupId":"OG002","value":"80.1","spread":"24.8"},{"groupId":"OG003","value":"73.1","spread":"18.8"}]}]}]},{"type":"SECONDARY","title":"Oxidative Stress and Inflammatory Markers: Interleukin 6 (IL6)","description":"Interleukin 6 (IL6)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"1.6"},{"groupId":"OG001","value":"4.2","spread":"3.2"},{"groupId":"OG002","value":"2.6","spread":"2.4"},{"groupId":"OG003","value":"3.5","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Oxidative Stress and Inflammatory Markers: TNFalpha","description":"TNFalpha","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.76","spread":"1.08"},{"groupId":"OG001","value":"1.71","spread":".80"},{"groupId":"OG002","value":"1.56","spread":".95"},{"groupId":"OG003","value":".91","spread":".46"}]}]}]},{"type":"SECONDARY","title":"Oxidative Stress and Inflammatory Markers: High-sensitivity C-reactive Protein (hsCRP)","description":"high-sensitivity C-reactive protein (hsCRP)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.19","spread":"3.84"},{"groupId":"OG001","value":"1.98","spread":"1.64"},{"groupId":"OG002","value":"1.43","spread":"1.11"},{"groupId":"OG003","value":"1.44","spread":"1.42"}]}]}]},{"type":"SECONDARY","title":"Oxidative Stress and Inflammatory Markers: Adiponectin","description":"adiponectin","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":"7.7"},{"groupId":"OG001","value":"14.9","spread":"10.8"},{"groupId":"OG002","value":"7.3","spread":"5.0"},{"groupId":"OG003","value":"5.8","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Oxidative Stress and Inflammatory Markers: Plasminogen Activator Inhibitor (PAI-1)","description":"Plasminogen activator inhibitor (PAI-1)","classes":[]},{"type":"SECONDARY","title":"Heart Rate Variability","description":"Measure of autonomic function; ratio of fastest to slowest heart rate during valsalva maneuver.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.37","spread":".17"},{"groupId":"OG001","value":"1.43","spread":".14"},{"groupId":"OG002","value":"1.59","spread":".19"},{"groupId":"OG003","value":"1.69","spread":".30"}]}]}]},{"type":"SECONDARY","title":"Arterial Stiffness (PWV)","description":"Pulse wave velocity by Sphygmacor as a measure of aortic stiffness in m/sec. Higher values reflect a stiffer vasculature.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.24","spread":"2.46"},{"groupId":"OG001","value":"9.91","spread":"3.30"},{"groupId":"OG002","value":"6.97","spread":"1.71"},{"groupId":"OG003","value":"7.4","spread":"1.00"}]}]}]},{"type":"SECONDARY","title":"Arterial Stiffness (AI)","description":"Augmentation index by Sphygmacor is a measure of aortic arterial stiffness. AI@75 is the ratio of augmented pressure/pulse pressure adjusted to a heart rate of 75.\n\nHigher values indicate stiffer vessels","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4","spread":"8.4"},{"groupId":"OG001","value":"19.7","spread":"10.0"},{"groupId":"OG002","value":"11.1","spread":"13.0"},{"groupId":"OG003","value":"12.4","spread":"12.7"}]}]}]},{"type":"SECONDARY","title":"Metabolic Markers: Continuous Glucose Monitoring Measures","description":"Continuous glucose monitoring measures for 3 days before clamp. Collected for participants with T1 Diabetes only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.82","spread":"1.2"},{"groupId":"OG001","value":"9.09","spread":"0.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.64","spread":"0.92"},{"groupId":"OG001","value":"3.64","spread":"0.66"}]}]}]},{"type":"SECONDARY","title":"Metabolic Markers: Mean 24 Hour Triglyceride and Glucose Levels","description":"mean glucose and triglycerides for the 24 hours before the 2nd overnight stay from 22 hourly measurements over 24 hours (except 0100 and 0300).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"135","spread":"28"},{"groupId":"OG001","value":"131","spread":"31"},{"groupId":"OG002","value":"87","spread":"10"},{"groupId":"OG003","value":"89","spread":"8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":"29"},{"groupId":"OG001","value":"68","spread":"33"},{"groupId":"OG002","value":"67","spread":"20"},{"groupId":"OG003","value":"83","spread":"27"}]}]}]},{"type":"SECONDARY","title":"Metabolic Markers: Insulin","description":"mean insulin for the 24 hours before the 2nd overnight stay from 22 hourly measurements over 24 hours (except 0100 and 0300).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":"25"},{"groupId":"OG001","value":"47","spread":"26"},{"groupId":"OG002","value":"20","spread":"6"},{"groupId":"OG003","value":"21","spread":"10"}]}]}]},{"type":"SECONDARY","title":"Metabolic Markers: Glycerol","description":"mean glycerol for the 24 hours before the 2nd overnight stay from 22 hourly measurements over 24 hours (except 0100 and 0300).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":"25"},{"groupId":"OG001","value":"75","spread":"20"},{"groupId":"OG002","value":"63","spread":"12"},{"groupId":"OG003","value":"69","spread":"14"}]}]}]},{"type":"SECONDARY","title":"Vascular Markers","description":"endothelin 1 measured as a marker of vascular damage","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.92","spread":"1.56"},{"groupId":"OG001","value":"4.9","spread":"0.91"},{"groupId":"OG002","value":"4.83","spread":"0.92"},{"groupId":"OG003","value":"4.12","spread":"1.00"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Other Mitochondrial Measures: Mito Content and Electron Transport Chain Complexes","description":"Mito content and electron transport chain complexes by western blot analysis.","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Oxidative Stress and Inflammatory Markers: Exploratory (Not Collected)","description":"thiobarbituric acid reactive substances (TBARs), glutathione disulfide (GSSG): reduced Glutathione (GSH) ratio; amplex red assay of hydrogen peroxide (H2O2) production,","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Counterregulatory Hormones","description":"Planned glucagon and cortisol as a markers of counteregulation, but not done due to financial limitations","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":10},"commonTop":[]}}}